NEWS AND MEDIA INFORMATION
OUR TECHNOLOGY IS BENEFITTING GLOBAL HEALTH. SHARE OUR PURPOSE.
NOVEMBER, 2023
Meet us at this year's BIO EUROPE in Munich from November 6-8 to discuss partnering opportunities with regard to our platform technology and vaccine candidates.
OCTOBER, 2023
Meet us in our start-up booth at the WORLD VACCINE CONGRESS from October 16-19 in Barcelona to discuss latest technology updates and recent vaccine developments. The WVC will also give plenty of room to discuss partnering opportunities and of course, to meet, learn from, and network with most influential leaders in the vaccine community!
JULY, 2022
First patient in! A major milestone was achieved with the start of first clinical trials in humans using our multivalent COVID-19 vaccine Prime-2-CoV, which was developed based on our proprietary Orf Virus based platform technology. The phase I clinical trials will take place at different sites in the EU and US, and will be managed by the Tropical Institute of the University Hospital of Tübingen and Speransa Therapeutics. If you want to participate in this study or are interested in further information, please follow this Link.
JUNE, 2021
Today we can announce that we have succesfully closed our seed financing with the High-Tech Gründerfonds. We are very happy to work together with the highly experienced team in order to build a strong and sustainable business.
APRIL, 2021
We are growing and found a new home - very happy to be moving in our first lab in the Forschungscampus BioMedTech in Reutlingen.
MARCH, 2021
Another milestone was reached as the BMWi again raised the funding for the COVID-19 vaccine development again substantially. Fighting the pandemic, this is a significant contribution throughtout the clinical development and emphasizes the trust of the ministry in the EXIST project "Impfkraft" potentially saving lives.
What are the advantages of the unique platform technology developed by PRIME? How far is PRIME in vaccine development? How did the incorporation of PRIME happen? What are the next entrepreneurial steps? Dr. Ralf Amann gives answers to all these and more questions in a detailed written German interview.
NOVEMBER, 2020
PRIME becomes part of the German Accelerator Life Sciences program! We are very happy about the great opportunity to work together with this highly skilled team in order to get our technology closer to market.
NOVEMBER, 2020
Together with the University Clinic of Tuebingen and ABL Europe, a global CDMO and subsidiary of the French bioindustrial group Institut Mérieux, we joined forces to bring our second generation COVID-19 vaccine closer to the clinics. Funded by the BMWi and developed in close alignment with the Paul-Ehrlich-Institut, ABL will now develop and manufacture the vaccine candidate in preparation for clinical trials according to a process initially developed in collaboration with the TH Mittelhessen University of Applied Sciences. For more information, please follow the link
OCTOBER, 2020
The BMWi has just again increased the funding for our COVID-19 vaccine development substantially. With this funding we will be able to examine our second generation vaccine candidate throughout the first two clinical phases in humans and on track to potentially enter the approval process in mid 2022. We are very grateful and happy about the opportunity to make a contribution in the fight against COVID-19.
SEPTEMBER, 2020
We are thrilled to announce that we were awarded second place in this year's Science4Life Venture Cup finale! The Science4Life Venture Cup is the largest business plan competition in Germany and open to all founders from the life sciences and chemistry sectors, which is specifically geared towards the requirements of both industries. In the frame of three stages we received support, further training and, last but not least, evaluation of our business idea exclusively by industry experts from the life sciences and chemistry sectors to sharpen our mission towards the commercialization of ORFV based vaccines.
JULY, 2020
We are happy to announce that the independent jury of experts from the BMWi funding program EXIST research transfer has just increased the funds again for our COVID-19 vaccine development. With our multivalent vaccine vector approach, we induce a strong SARS-CoV-2-specific T cell response in addition to a broad antibody-based immunity against several Sars-CoV-2 antigens. This allows the vaccine to remain effective also against mutated strains of SARS-CoV-2 and to universally boost the immunity of previously immunized or infected individuals. With the outbreak of the COVID-19 pandemic in Germany, we have focused entirely on the development of a comprehensive vaccine against the novel corona virus and were able to convince the jury with achieving several milestones. Thus, we have obtained very promising preliminary results of our vaccine candidates in preclinical studies and just recently received positive feedback from the Paul Ehrlich Institute (PEI) for the vaccine manufacturing from August 2020 for human testing. As a next step, necessary tests in non-human primates will be carried out, while discussions with international partners are ongoing and supported by renowned clinicians and experts in the field of COVID-19.
JULY, 2020
We are very proud to join the German Accelerator Southeast Asia program! As we race to produce our COVID-19 vaccine, German Accelerator will support us in search for production partners and key hospitals in Asia!
MAY, 2020
In the frame of this year's
Science4Life Technology Slam, PRIME will pitch its technology and be available to get in contact in a virtual exhibition stand. We look forward meeting you there!
APRIL, 2020
Meet us at the
#PartneringAgainstCovid19
from May 4th - 6th to discuss partnering opportunities concerning our COVID-19 vaccine development, as well as to learn more about our technology and fields of application!
APRIL, 2020
Happy to announce that the Carl Zeiss Foundation committed to support our
COVID-19 vaccine development
with 150.000 €.
APRIL, 2020
The EXIST program reacts to current corona crisis
granting the project "Impfkraft"
at the University of Tübingen with additional funds from the BMWi. We gratefully acknowledge this commitment to develop a polyvalent vaccine against COVID-19.
MARCH, 2020
Proud to announce that we are among the winners of this year's
Science4Life Venture Cup concept phase.
OCTOBER, 2019
Three members of the ImpfKraft Team, Melanie Müller, Ralf Amann and Ferdinand Salomon, incorporate Prime Vector Technologies GmbH.
November, 2018
Members of the Exist Project Impfkraft meet global players of the vaccination industry at BioEurope 2018, Partnering Conference in Copenhagen, 5th - 7th of November, 2018.
BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
SEPTEMBER, 2018
Melanie Müller, CSO at PRIME wins the 2018 poster prize at 12th Vaccine Congress in Budapest, Hungary.
The awarded poster was entitled “The mechanism of immune stimulation by Orf virus – a novel viral vector for therapeutic vaccinations” and described important results on the mode of action of the ORFV technology.”
JUNE, 2018
The Project "Impfkraft" raised a seven digits, three years Exist-Transfer of Research Grant, commencing on June 1st, 2018.
JULY, 2016
Members of the Exist Project Impfkraft secured 3rd price in the 2016 Science2Start competition of BioRegio Stern.
3rd prize for “Immune Modulating Orf Virus – IMOrf” from Melanie Mueller, Dr. Alena Reguzova, Ferdinand Salomon, Dr. Thomas Feger, Dr. Hanns-Joachim Rziha and Dr. Ralf Amann at the University of Tübingen, Inter-Faculty Institute for Cell Biology, Immunology Department.
"The Orf virus vector (ORFV) is used as a basis for producing recombinant (genetically modified) vaccines. This research team is developing a platform technology that uses the ORFV as an immune modulator to influence the immune system in a targeted way. The vaccines can then be used to prevent infectious diseases, as well as for therapeutic tumour vaccines and treating autoimmune diseases. This innovative technology makes it possible to precisely determine the location and type of the immune response initiated."
Source:
BioRegio Stern
DECEMBER, 2015
Members of the Exist Project Impfkraft secured an additional funding for the project "Orf-Virusvektor-basierte, therapeutische Tumorimpfstoffe gegen HPV-induzierte Tumoren" from Innovation Grant of the University of Tuebingen. Innovation Grant is an initiative of the Excellence Initiative of the University of Tuebingen.
JULY, 2013
Members of the Exist Project Impfkraft secured 3rd price in the 2013 Science2Start competition of BioRegio Stern.
Third place went to Jörg Rohde and Ralf Amann from the Institute of Immunology, Laboratory for Molecular Immunopathogenesis and Virus Vectors (working group H-J Rziha) of the University of Tübingen.
"The prize was awarded for their development of 'Individualized, therapeutic vaccines against HPV-induced tumors using a viral vector' . Seven percent of all cancers are due to human papillomavirus (HPV) infections, and the goal of the new therapy is to create tailored vaccines that are composed of defined viral antigens and patient-specific mutations. The use of multiple antigens makes the tumor more identifiable by the immune system."
Source:
BioRegio Stern
MARCH, 2013
Members of the Exist Project Impfkraft won first price in the feasibility phase of GO-Bio Innovation Academy - Biotechnology.
